BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu F, Moorman AC, Tong X, Gordon SC, Rupp LB, Lu M, Teshale EH, Spradling PR, Boscarino JA, Trinacty CM, Schmidt MA, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators, Holmberg SD, Teshale EH, Spradling PR, Moorman AC, Xing J, Tong X, Xu F, Gordon SC, Nerenz DR, Lu M, Lamerato L, Wang Y, Rupp LB, Akkerman N, Oja-Tebbe N, Zhang T, Li J, Sitarik A, Larkin D, Boscarino JA, Daar ZS, Curry PJ, Smith RE, Vijayadeva V, Parker JV, Schmidt MA, Donald JL, Keast EM. All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus. Clin Infect Dis. 2016;62:289-297. [PMID: 26417034 DOI: 10.1093/cid/civ860] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Corma-Gómez A, Morano L, Téllez F, Rivero-Juárez A, Real LM, Alados JC, Ríos-Villegas MJ, Vera-Méndez FJ, Muñoz RP, Geijo P, Macías J, Pineda JA; RIS-HEP13 and GEHEP 011 study groups. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. AIDS 2019;33:1167-74. [PMID: 30845068 DOI: 10.1097/QAD.0000000000002186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
2 Leidner AJ, Chesson HW, Spradling PR, Holmberg SD. Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Appl Health Econ Health Policy 2017;15:65-74. [PMID: 27480538 DOI: 10.1007/s40258-016-0261-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
3 Gordon S, Lee J, Smith N, Dieterich D. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States. Expert Rev Pharmacoecon Outcomes Res 2020;20:251-7. [PMID: 31204882 DOI: 10.1080/14737167.2019.1629291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Nabatchikova EA, Abdurakhmanov DT, Nikulkina EN, Rozina TP, Tanaschuk EL, Nikiforova NV, Adonyeva VS, Moiseev SV. [The long-term prospective study of patients with liver cirrhosis after elimination of the hepatitis C virus]. Ter Arkh 2020;92:34-42. [PMID: 32598716 DOI: 10.26442/00403660.2020.02.000511] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Wang L, Xu Y, Zhang S, Bibi A, Xu Y, Li T. The AST/ALT Ratio (De Ritis Ratio) Represents an Unfavorable Prognosis in Patients in Early-Stage SFTS: An Observational Cohort Study. Front Cell Infect Microbiol 2022;12:725642. [DOI: 10.3389/fcimb.2022.725642] [Reference Citation Analysis]
6 Cengiz M, Ozenirler S. Serum Peptidyl-prolyl Cis-trans Isomerase NIMA-interacted 1 (Pin1) as a Non-invasive Marker for Liver Fibrosis due to Chronic Hepatitis C Virus. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.116687] [Reference Citation Analysis]
7 Rosińska M, Parda N, Kołakowska A, Godzik P, Zakrzewska K, Madaliński K, Zieliński A, Boguradzka A, Gierczyński R, Stępień M. Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-2016. PLoS One 2017;12:e0185055. [PMID: 28931062 DOI: 10.1371/journal.pone.0185055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
8 Bach TA, Zaiken K. Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting. Am J Health Syst Pharm 2017;74:S1-9. [PMID: 28213381 DOI: 10.2146/ajhp160567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Lee YB, Nam JY, Lee JH, Chang Y, Cho H, Cho YY, Cho EJ, Yu SJ, Kim HY, Lee DH, Lee JM, Hwang SG, Kim YJ, Yoon JH. Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. Sci Rep 2018;8:13651. [PMID: 30209336 DOI: 10.1038/s41598-018-31839-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Klevens RM, Canary L, Huang X, Denniston MM, Yeo AE, Pesano RL, Ward JW, Holmberg S. The Burden of Hepatitis C Infection–Related Liver Fibrosis in the United States. Clin Infect Dis 2016;63:1049-55. [DOI: 10.1093/cid/ciw468] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
11 Barth C, Neusser S, Biermann J, Wasem J, Berg T, Wiegand J, Wolffram I, Petroff D, Aidelsburger P, Grünbauer A, Neumann A. Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting. Scand J Gastroenterol 2018;53:76-82. [PMID: 29065740 DOI: 10.1080/00365521.2017.1390599] [Reference Citation Analysis]
12 Puchades Renau L, Berenguer M. Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies: Overview and history of hepatitis C therapies. Hemodialysis International 2018;22:S8-S21. [DOI: 10.1111/hdi.12647] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
13 Fontana RJ, Lens S, McPherson S, Elkhashab M, Ankoma-Sey V, Bondin M, Dos Santos AGP, Xue Z, Trinh R, Porcalla A, Zeuzem S. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study. Adv Ther 2019;36:3458-70. [PMID: 31646465 DOI: 10.1007/s12325-019-01123-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Turner BJ, Wang C, Melhado TV, Bobadilla R, Jain MK, Singal AG. Significant Increase in Risk of Fibrosis or Cirrhosis at Time of HCV Diagnosis for Hispanics With Diabetes and Obesity Compared With Other Ethnic Groups. Clinical Gastroenterology and Hepatology 2019;17:1356-63. [DOI: 10.1016/j.cgh.2018.11.059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Cheng PN, Chiu YC, Chiu HC, Chien SC. The Application of Liver Stiffness Measurement in Residents Without Overt Liver Diseases Through a Community-Based Screening Program. Medicine (Baltimore) 2016;95:e3193. [PMID: 27015215 DOI: 10.1097/MD.0000000000003193] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
16 Younossi Z, Blissett D, Blissett R, Henry L, Younossi Y, Beckerman R, Hunt S. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. Liver Int 2018;38:258-65. [PMID: 28719013 DOI: 10.1111/liv.13519] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
17 Axley P, Mudumbi S, Sarker S, Kuo YF, Singal AK. Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications. PLoS One 2018;13:e0197117. [PMID: 29746540 DOI: 10.1371/journal.pone.0197117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
18 Laursen TL, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol 2020; 26(22): 2931-2947 [PMID: 32587440 DOI: 10.3748/wjg.v26.i22.2931] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Moorman AC, Rupp LB, Gordon SC, Zhong Y, Xing J, Lu M, Boscarino JA, Schmidt MA, Daida YG, Teshale EH, Spradling PR, Holmberg SD; CHeCS Investigators. Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings. Infect Dis Clin North Am. 2018;32:253-268. [PMID: 29778254 DOI: 10.1016/j.idc.2018.02.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
20 Caro L, Wenning L, Guo Z, Fraser IP, Fandozzi C, Talaty J, Panebianco D, Ho M, Uemura N, Reitmann C, Angus P, Gane E, Marbury T, Smith WB, Iwamoto M, Butterton JR, Yeh WW. Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor. Antimicrob Agents Chemother 2017;61:e00813-17. [PMID: 28947470 DOI: 10.1128/AAC.00813-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
21 Zarębska-Michaluk D. Viral hepatitis C treatment shortening - what is the limit? Clin Exp Hepatol 2019;5:265-70. [PMID: 31893236 DOI: 10.5114/ceh.2019.88085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Gane E, Poordad F, Zadeikis N, Valdes J, Lin CW, Liu W, Asatryan A, Wang S, Stedman C, Greenbloom S, Nguyen T, Elkhashab M, Wörns MA, Tran A, Mulkay JP, Setze C, Yu Y, Pilot-Matias T, Porcalla A, Mensa FJ. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease. Clin Infect Dis 2019;69:1657-64. [PMID: 30923816 DOI: 10.1093/cid/ciz022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
23 Boscarino JA, Moorman AC, Rupp LB, Zhou Y, Lu M, Teshale EH, Gordon SC, Spradling PR, Schmidt MA, Trinacty CM, Zhong Y, Holmberg SD, Holtzman D; Chronic Hepatitis Cohort Study (CheCS) Investigators. Comparison of ICD-9 Codes for Depression and Alcohol Misuse to Survey Instruments Suggests These Codes Should Be Used with Caution. Dig Dis Sci 2017;62:2704-12. [PMID: 28879547 DOI: 10.1007/s10620-017-4714-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
24 Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect 2016;22:826-32. [PMID: 27592089 DOI: 10.1016/j.cmi.2016.08.025] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
25 Bruden DJT, McMahon BJ, Townshend-Bulson L, Gounder P, Gove J, Plotnik J, Homan C, Hewitt A, Barbour Y, Spradling PR, Simons BC, McArdle S, Bruce M. Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort. Hepatology 2017;66:37-45. [PMID: 28195349 DOI: 10.1002/hep.29115] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
26 Turner BJ, Liang Y, Singal AG. FIB-4 and imaging for measuring fibrosis in hepatitis C virus. Eur J Gastroenterol Hepatol 2017;29:192-8. [PMID: 27755232 DOI: 10.1097/MEG.0000000000000766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
27 Wörns MA, Galle PR, Zeuzem S, Schirmacher P, Manns M, Vogel A. Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. Dtsch Arztebl Int 2017;114:597-602. [PMID: 28927498 DOI: 10.3238/arztebl.2017.0597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
28 Zarębska-michaluk D, Jaroszewicz J, Janczewska E, Berak H, Horban A, Sitko M, Garlicki A, Dobracka B, Czauż-andrzejuk A, Dybowska D, Halota W, Pawłowska M, Tudrujek-zdunek M, Tomasiewicz K, Mazur W, Deroń Z, Belica-wdowik T, Baka-ćwierz B, Buczyńska I, Simon K, Piekarska A, Białkowska-warzecha J, Lorenc B, Krygier R, Staniaszek A, Klapaczyński J, Citko J, Socha Ł, Wawrzynowicz-syczewska M, Laurans Ł, Flisiak R. Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.80761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Bixler D, Zhong Y, Ly KN, Moorman AC, Spradling PR, Teshale EH, Rupp LB, Gordon SC, Boscarino JA, Schmidt MA, Daida YG, Holmberg SD, Holmberg SD, Teshale EH, Spradling PR, Moorman AC, Xing J, Zhong Y, Gordon SC, Nerenz DR, Lu M, Lamerato L, Li J, Rupp LB, Akkerman N, Zhang T, Trudeau S, Zhou Y, Wu K, Boscarino JA, Daar ZS, Smith RE, Daida YG, Trinacty CM, Lai JW, Wong CP, Schmidt MA, Donald JL; CHeCS Investigators. Mortality Among Patients With Chronic Hepatitis B Infection: The Chronic Hepatitis Cohort Study (CHeCS). Clinical Infectious Diseases 2019;68:956-63. [DOI: 10.1093/cid/ciy598] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
30 Ng A. Oversimplification of the link between hepatitis C treatment and hepatocellular carcinogenesis? Rev Gastroenterol Mex (Engl Ed) 2022:S2255-534X(21)00145-6. [PMID: 34996738 DOI: 10.1016/j.rgmxen.2021.05.014] [Reference Citation Analysis]
31 Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol 2017; 9(7): 352-367 [PMID: 28321272 DOI: 10.4254/wjh.v9.i7.352] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
32 Mederacke I, Filliol A, Affo S, Nair A, Hernandez C, Sun Q, Hamberger F, Brundu F, Chen Y, Ravichandra A, Huebener P, Anke H, Shi H, Martínez García de la Torre RA, Smith JR, Henderson NC, Vondran FWR, Rothlin CV, Baehre H, Tabas I, Sancho-Bru P, Schwabe RF. The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver. Sci Transl Med 2022;14:eabe5795. [PMID: 35385339 DOI: 10.1126/scitranslmed.abe5795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
33 Serviddio G, Villani R. The effect of direct-acting antivirals on hepatocellular carcinoma recurrence: still waiting for the turning point. Hepatobiliary Surg Nutr 2019;8:525-6. [PMID: 31673546 DOI: 10.21037/hbsn.2019.05.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol 2019;54:752-61. [PMID: 30868245 DOI: 10.1007/s00535-019-01569-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
35 Jacobson IM, Lawitz E, Kwo PY, Hézode C, Peng CY, Howe AYM, Hwang P, Wahl J, Robertson M, Barr E, Haber BA. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Gastroenterology 2017;152:1372-1382.e2. [PMID: 28193518 DOI: 10.1053/j.gastro.2017.01.050] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 11.2] [Reference Citation Analysis]
36 De Vincentis A, Costanzo L, Vespasiani-Gentilucci U, Picardi A, Bandinelli S, Ferrucci L, Antonelli Incalzi R, Pedone C. Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people. Dig Liver Dis 2019;51:1330-6. [PMID: 30808572 DOI: 10.1016/j.dld.2019.01.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
37 Hofmeister MG, Xing J, Foster MA, Augustine RJ, Burkholder C, Collins J, McBee S, Thomasson ED, Thoroughman D, Weng MK, Spradling PR. Factors Associated With Hepatitis A Mortality During Person-to-Person Outbreaks: A Matched Case-Control Study-United States, 2016-2019. Hepatology 2021;74:28-40. [PMID: 33217769 DOI: 10.1002/hep.31645] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
38 Wurcel AG, Guardado R, Beckwith CG. Hepatitis C Virus Is Associated With Increased Mortality Among Incarcerated Hospitalized Persons in Massachusetts. Open Forum Infect Dis 2021;8:ofab579. [PMID: 34934776 DOI: 10.1093/ofid/ofab579] [Reference Citation Analysis]
39 Lawitz EJ, Shevell DE, Tirucherai GS, Du S, Chen W, Kavita U, Coste A, Poordad F, Karsdal M, Nielsen M, Goodman Z, Charles ED. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology 2022;75:912-23. [PMID: 34605045 DOI: 10.1002/hep.32181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]